

Journal of Visualized Experiments

Spatio-temporal in vivo imaging of ocular drug delivery systems using fiberoptic confocal laser microendoscopy --Manuscript Draft--

Article Type:	Methods Article - JoVE Produced Video
Manuscript Number:	JoVE62685R2
Full Title:	Spatio-temporal in vivo imaging of ocular drug delivery systems using fiberoptic confocal laser microendoscopy
Corresponding Author:	Su Yin Chaw, Ph.D. Duke-NUS: Duke-NUS Medical School Singapore, Singapore SINGAPORE
Corresponding Author's Institution:	Duke-NUS: Duke-NUS Medical School
Corresponding Author E-Mail:	gmschaw@nus.edu.sg;chaw.suyin@yahoo.com.sg
Order of Authors:	Su Yin Chaw, Ph.D. Tina Tzee Ling Wong Subbu Venkatraman Ann-Marie Chacko
Additional Information:	
Question	Response
Please specify the section of the submitted manuscript.	Bioengineering
Please indicate whether this article will be Standard Access or Open Access.	Standard Access (\$1400)
Please indicate the city, state/province, and country where this article will be filmed . Please do not use abbreviations.	Singapore
Please confirm that you have read and agree to the terms and conditions of the author license agreement that applies below:	I agree to the Author License Agreement
Please provide any comments to the journal here.	We were approached by Dr Kyle Jewhurst for submission to the Methods Collections on Nanocarriers as Multifunctional Platforms for Biomolecule Delivery. We have interest in this collection if accepted.
Please confirm that you have read and agree to the terms and conditions of the video release that applies below:	I agree to the Video Release

TITLE:

Spatio-Temporal *In Vivo* Imaging of Ocular Drug Delivery Systems using Fiberoptic Confocal Laser Microendoscopy

AUTHORS AND AFFILIATIONS:

Su Yin Chaw^{1,2,*}, Tina Tzee Ling Wong^{3,4}, Subbu Venkatraman², Ann-Marie Chacko¹

¹Laboratory for Translational and Molecular Imaging, Cancer and Stem Cell Biology Programme, Duke-NUS Medical School, Singapore

²School of Materials Science and Engineering, Nanyang Technological University, Singapore

³Singapore National Eye Centre, Singapore

⁴Singapore Eye Research Institute, Singapore

Email addresses of co-authors:

Su Yin Chaw (gmschaw@nus.edu.sg)

Tina Tzee Ling Wong (tina.wong.t.l@singhealth.com.sg)

Subbu Venkatraman (subbu@nus.edu.sg)

Ann-Marie Chacko (ann-marie.chacko@duke-nus.edu.sg)

*Corresponding author

Su Yin Chaw (gmschaw@nus.edu.sg)

KEYWORDS:

In vivo Imaging, ocular therapy, liposomes, fluorescence imaging, drug delivery systems, nanocarriers

SUMMARY:

We present a protocol for the use of fiberoptic confocal laser microendoscopy (CLM) to non-invasively study the spatio-temporal distribution of liposomes in the eye after subconjunctival injection.

ABSTRACT:

Subconjunctival injection is an attractive route to administer ocular drugs due to easy trans-scleral access that bypasses anterior ocular barriers, such as the cornea and conjunctiva. While therapeutic effects and pharmacokinetics of the drugs upon subconjunctival injection have been described in some studies, very few assess the ocular distribution of drugs or drug delivery systems (DDS). The latter is critical for the optimization of intraocular DDS design and drug bioavailability to achieve the desired ocular localization and duration of action (e.g., acute versus prolonged). This study establishes the use of fiberoptic confocal laser microendoscopy (CLM) to qualitatively study the ocular distribution of fluorescent liposomes in real-time in live mice after sub-conjunctival injection. Being designed for *in vivo* visual inspection of tissues at the microscopic level, this is also the first full description of the CLM imaging method to study spatio-temporal distribution of injectables in the eye after subconjunctival injection.

INTRODUCTION:

The blood clearance, tissue distribution, and target occupancy of drugs in living systems are pillars to understanding *in vivo* drug disposition. In preclinical animal models, these parameters are typically assessed by frequent blood and tissue sampling at particular time points post drug administration. However, these procedures are generally invasive, often include non-survival measurements, and necessitate large animal cohorts for statistical powering. There might be extra cost and time incurred, along with ethical concerns for excessive use of animals. As a result, non-invasive imaging is fast becoming an integral step in biodistributions studies. Confocal laser microendoscopy (CLM^{1,2}) is well-suited for ocular applications to non-invasively image the spatio-temporal distribution of therapeutics in the eyes of live animals with high sensitivity and high resolution^{1,3,4}.

CLM has the potential to facilitate robust screening of ocular drug delivery systems (DDS), such as nanocarrier liposomes, prior to comprehensive quantification of the DDS and drug bioavailability. Liposomes are attractive for their flexibility in tuning their physicochemical and biophysical properties^{5–11} to encapsulate a large variety of therapeutic cargo and control the tissue site of drug release and duration of action. Liposomes have been used in ocular applications for the delivery of large molecules, such as monoclonal antibody bevacizumab¹², and small molecules like cyclosporine¹³ and ganciclovir¹⁴. They showed a longer biological half-life and prolonged therapeutic effect compared to non-liposomal “free drug” administrations. However, drug distribution in ocular tissue is typically extrapolated from drug concentrations in fluid components of the eye (i.e., blood, aqueous humor, and vitreous humor^{15–17}). As the initial *in vivo* fate of the loaded drug cargo is defined by the properties of the nanocarrier itself, CLM imaging of the fluorescent liposomes can serve as a surrogate for the drug to reveal tissue targeting and *in situ* tissue residence times. Furthermore, visual evidence of delivery with CLM can steer DDS re-design, evaluate therapeutic benefits of the drug, and perhaps even predict adverse biological events (e.g., tissue toxicity due to undesirable localization of DDS for protracted periods of time).

Herein, a step-by-step procedure is detailed on how to study the ocular biodistribution of liposomes in live mice with a dual-band CLM system. This specific CLM system can detect two-color fluorescence (with green and red excitation lasers at 488 nm and 660 nm) in real-time, with a frequency of 8 frames/s. By physically placing the detection probe on the eye, the protocol demonstrates image acquisition and analysis of green-fluorescent liposomes upon subconjunctival administration in mice pre-injected intravenously (IV) with 2% Evans Blue (EB) dye. EB dye helps visualize the vascularized structures in the red fluorescence channel. We show representative results from a study assessing 100 nm neutral liposomes composed of the phospholipid POPC (i.e., 1-palmitoyl-2-oleoyl-glycero-3-phosphocholine) and doped with fluorescein-tagged phospholipid FI-DHPE (i.e., *N*-(fluorescein-5-thiocarbamoyl)-1,2-dihexadecanoylsn-glycero-3-phosphoethanolamine) at a ratio of 95% POPC: 5% FI-DHPE (**Figure 1B**). CLM is able to capture the green fluorescein-tagged liposomes at 15 μm axial and 3.30 μm lateral resolution by delineation of EB-stained ocular tissue boundaries.

PROTOCOL:

All methods described here have been approved by the Institutional Animal Care and Use Committee (IACUC) at SingHealth (Singapore). Female C57BL/6 J mice (6–8 weeks old; 18–20 g) were obtained from InVivos, Singapore, and housed in a temperature and light-controlled vivarium of Duke-NUS Medical School, Singapore. Animals were treated in accordance with the guidelines from the Association for Research in Vision and Ophthalmology (ARVO) statement for the use of animals in ophthalmic and vision research.

NOTE: A flow chart highlighting the main procedures is shown in **Figure 2**.

1. Preparation of contrast agents: Evans Blue (EB) and liposomes

1.1. For 2% EB dye solution, dissolve 1 g of EB in 50 mL of sterile saline. Filter the solution using 0.22 μm filters into 1.5 mL sterile tubes and store them at room temperature for later use.

1.2. For green-fluorescent liposomes, add POPC/Fl-DHPE (95:5), chloroform/methanol (2:1) into a 100 mL round bottom flask. Use a rotary evaporator at 150 rpm at 40 $^{\circ}\text{C}$ for 1 h, with vacuum maintained at 0 mbar¹ to create a thin lipid film.

NOTE: When comparing effects of liposomal properties (e.g., size, charge, lipid saturation, lipid chain length) on distribution, maintain a fixed percentage of Fl-DHPE or other fluorescent lipids to confirm that the results observed are due to the effect of the properties tested, and not to the variable load of large hydrophobic dyes.

1.3. Hydrate the lipid film with phosphate-buffered saline (to achieve 26.3 mM of fluorescent liposomes) at 40 $^{\circ}\text{C}$ to form multi-lamellar vesicles (MLV). Load the MLVs into a glass syringe for manual extrusion (30 times using a 0.08 μm pore size polycarbonate filter) to achieve the desired size of 100 nm.

NOTE: The temperature for hydration must be higher than the transition temperature of the lipids.

1.4. Filter the liposomes by passing them through a 0.22 μm sterile syringe filter. Confirm the hydrodynamic diameter (D_H) of the liposomes using a dynamic light scattering system.

2. Administration of EB and liposomes in live mice

2.1. Inject mouse with EB IV (intravenous) via the tail vein (2.5 mg/kg), 2 h before subconjunctival injection.

2.2. For subconjunctival injection, first, sedate the mouse using 5% isoflurane via inhalation in an induction chamber to achieve an adequate plane of anesthesia. Transfer the mouse to a nose

cone and maintain sedation at 2%–2.5% of isoflurane while on a heating pad throughout the procedure.

2.3. Trim the eyelashes on the eye to be injected and instill a drop of topical anesthetic 0.5% proxymetacaine hydrochloride solution directly on the eye.

2.4. Load a 10 μ L glass syringe (with 32 G needle) with fluorescent liposomes (FI-DHPE: 0.78 mg/kg) and dispel all air bubbles in the syringe prior to injection.

NOTE: Up to 20 μ L of injectate can be accommodated in the subconjunctival space of mice^{18,19}.

2.5. Using a tweezer, lift the conjunctiva slightly and inject slowly into the subconjunctival space (**Figure 1A**). Withdraw the needle slowly to prevent backflow. Ensure that a visible bleb filled with fluorescent liposomes is formed (**Figure 1C**).

2.6. Administer a drop of antibiotic 1% fusidic acid on the eye after the injection and monitor the mouse until it regains consciousness.

3. CLM set-up

3.1. Switch on the CLM system and make sure both the connector and the distal tip of the scanning probe are clean.

3.2. Clean the connector of the scanning probe using an optical connector cleaner by following the manufacturer's instructions.

3.2.1. Press the ratchet (often colored) of the optical connector cleaner to reveal a cleaning ribbon.

3.2.2. Position the connector in contact with the cleaning ribbon and slide the connector along the ribbon while maintaining contact.

3.3. Clean the distal tip (also known as the scanning tip) of the probe by dipping it into the cleansing solution, followed by the rinsing solution provided by the manufacturer. A cotton tip applicator can also be used for more thorough cleaning if the tip is very dirty.

3.4. Connect the probe to the CLM system. Choose the Field of view (FOV) and the location for the acquisition files at this point.

NOTE: Adjust the laser intensity at this step to ensure that fluorescence detection for FI-DHPE is in the linear range. Laser intensity is to be kept consistent for comparison between images taken at different time points.

3.5. Allow the system to warm up for 15 min as instructed and use the calibration kit to calibrate the system according to the manufacturer's instructions.

NOTE: In the calibration kit, there are three vials for each laser containing the following solutions: cleansing solution, rinsing solution, and fluorophore 488/660 nm solution for internal calibration. The calibration steps are prompted by the system and are to be followed accordingly.

3.5.1. Immerse the tip in the cleansing vial followed by the rinsing vial (5 s in each vial). Leave it in the air for background recording for both channels.

NOTE: This step is very crucial as it normalizes the background values from different fibers of the probe and ensures image uniformity.

3.5.2. Immerse the tip in the cleansing vial followed by the rinsing vial (5 s in each vial). Immerse the tip in fluorophore 488 nm vial for 5 seconds to normalize signal values from different fibers in the probe.

3.5.3. Immerse the tip in the cleansing vial followed by the rinsing vial (5 s in each vial). Immerse the tip in the rinsing vial until the fluorescence signal recorded in 3.5.2. disappears. Immerse the tip in fluorophore 660 nm vial to normalize signal values from different fibers in the probe.

NOTE: Follow all the calibration steps in order to achieve proper calibration and optimal image quality.

3.6. After calibrating the probe, check to make sure the background values for the probes are as low as possible. For the CLM system used, keep the background values below 100. Perform repeated cleaning of the probe with a cotton tip applicator and calibration if values are above 100/defined user value or if the probe appears to be dirty. This is to ensure that the background noise is kept around the same value.

NOTE: It is important to define the maximum background value (for example, 100 as stated in step 3.6) to ensure that probe conditions are similar. This will allow proper quantitative comparison between images taken at different time points. The value may differ in different systems and probe conditions.

3.7. Switch on the animal temperature controller (ATC). Adjust the ATC to 37 °C. Cover the heating pad with a surgical drape and fix the nose cone on the heating pad.

NOTE: ATC with an attached heating pad is required to ensure that the animal is kept warm throughout the imaging duration.

3.8. Clamp the stand of the dissecting microscope to the tabletop to secure it. Rotate and adjust the eyepiece of the microscope to view the mouse eye ergonomically through the

eyepiece when the user is seated (make the adjustments after placing the animal).

3.9. Sedate the mouse using 5% isoflurane in an induction chamber. Transfer the mouse to the nose cone once the animal is non-responsive and maintain sedation at 2%–2.5% isoflurane while on a heating pad throughout the procedure.

3.10. Trim the eyelashes of the mouse and instill a drop of anesthetic 0.5% proxymetacaine hydrochloride solution onto the eye.

3.11. To make sure the eyes are clean, drop a few drops of saline to wash the ocular surface.

3.12. Adjust the microscope so that the mouse eye is in direct focus at 0.67x magnification.

NOTE: Make sure to lubricate the eyes with saline. If the eyes are not lubricated throughout the imaging session, they can get dry, causing the lens to crystallize. As a result, during CLM imaging, the lens can emit a background red fluorescence.

4. Live imaging of mouse eyes with CLM and acquisition

4.1. Turn on the laser, place the probe on the eye and start recording acquisition to observe the fluorescence in the eye at the regions indicated on the eye map in **Figure 3**.

NOTE: Hold the probe is like a pen with the distal end of the probe directly onto the region to be imaged.

4.2. Stop the recording when all regions have been flagged and labeled. The acquisition files will be saved automatically in the file location chosen in step 3.4.

NOTE: The file will be saved as a video file which can be exported to individual images. Label the flag according to the eye map to know exactly the location of the probe at the exact frame the recording was done.

5. Image analysis

5.1. Use the same CLM acquisition software, export the image acquisition files for further analysis. Click on **File | Export** and choose the format to be exported to. Mkt format files will allow adjustments of look up table (LUT) and further exports to image file formats using the CLM viewer software.

5.2. For accurate comparison of fluorescence intensity, use the same LUT adjusted for each channel when exporting all image files.

NOTE: Choose the minimum and maximum LUT threshold with respect to those of the control

mouse (with no liposomes injected) to minimize background fluorescence readings.

5.3. Open the image in an appropriate image processing software/freeware program (e.g., ImageJ). Draw the region of interest (ROI).

NOTE: ROI here refers to the region of interest in the processing program. In most cases, ROI will be the whole image scanned. However, in the case of imaging the limbus, the probe cannot just get the image of the limbus separately. Therefore, an ROI has to be drawn to 'quantify' the fluorescence in the limbus region, as drawn in **Figure 4**. To keep the ROI consistent, use the same ROI across all images.

5.4. Measure and record the ROI values for green fluorescence. Enter the values in a spreadsheet. Tabulate the average and fluorescence intensity (a.u.) values of the ROI.

6. Histology assessment

6.1. Sacrifice the mouse by cervical dislocation under inhalational anesthesia (2.5% isoflurane).

6.2. Enucleate the eye and fix the eye in 1 mL of 4% formaldehyde or 10% formalin solution overnight.

6.3. Trim excess fats and embed the eye in the Optimal Cutting Temperature (OCT) compound and keep it frozen in a -80 °C freezer for at least one day.

6.4. Cut sections of 5 µm thickness in the cryostat with cutting temperature maintained at 20 °C. Transfer the section to a Poly-L-Lysine-coated microscope slide.

NOTE: Histology can serve as additional validation of the distribution of DDS. However, it requires additional optimization, technical expertise, and sacrifice of animals which the study aims to reduce by using CLM.

REPRESENTATIVE RESULTS:

The protocol demonstrates the utility of CLM to assess the spatio-temporal ocular distribution of green fluorescent liposomes administered through subconjunctival injection. To make use of the dual-color capability (488 nm and 660 nm excitation wavelengths) of the CLM system, 100 nm neutral POPC liposomes to be injected were doped with 5% FI-DHPE (composition and characterization data are shown in **Figure 1B**), and EB was injected IV to identify landmarks in the eye. The presence of a thin layer of episclera and the conjunctiva, which are both highly vascularized, allows the sclera region to be stained red with EB (**Figure 4A**, labeled as S), while the cornea which does not contain any vasculature (**Figure 4A**, labeled as C), does not get stained and appears black. This enables a distinct differentiation between both regions during fluorescence imaging.

The representative results are from a distribution study spanning over 7 days ($n = 4$ mice). As fluorescence intensities in the images for day 1 and day 3 were high (**Figure 5B**), the pixel intensities were reduced for better visualization. Actual values of the fluorescence intensity are reflected in the graphs (**Figure 6**). To ensure that observations from the images were due to fluorescence from the liposomes and not free dye, which might have dislodged from the liposomes, control mice injected with fluorescein (FI) dye was included (**Figure 5A**).

A reduction in the liposomes (by proxy of the decrease in green fluorescent signal) was observed in both the limbus and sclera regions over time. As the liposomes were injected from the temporal to the superior region of the subconjunctival space (**Figure 3**), they were naturally placed right on top of the temporal and superior sclera (**Figure 4B**) before reaching other regions of the subconjunctival space. On day 1 post-injection, fluorescence detected in the sclera was up to 6-times higher than the limbus for both temporal and superior regions (**Figure 6**). By day 3 and day 7, a significant reduction of liposomes was observed in the sclera (60% from day 1 to day 3 ($\text{day}_{1 \rightarrow 3}$) and 88% from day 3 to day 7 ($\text{day}_{3 \rightarrow 7}$)) in the temporal region, with a reduction of 66% and 93% for $\text{day}_{1 \rightarrow 3}$ and $\text{day}_{3 \rightarrow 7}$ in the superior regions, respectively, $p < 0.001$) (**Figure 6**). This reduction was attributed to the ocular clearance mechanisms through blood and/or lymphatic vessels found at the conjunctiva and episclera. The liposomes could also have diffused through the sclera and be cleared by the choroid, which is also highly vascularized.

The liposomes were found to have cleared in a slower manner in the limbus. For temporal limbus and superior limbus, the changes in fluorescence signals from day 1 to day 3 post-injection were not significant, indicating that neutral liposomes have a preference to the limbus region, particularly the corneal periphery (**Figure 5B**). Liposomes in the limbus region started clearing from day 3 ($\text{d}_{3 \rightarrow 7}$: -89% for temporal ($p < 0.01$), and -53% for superior ($p < 0.05$)). By day 7, more than 90% of liposomes were cleared from all limbus regions ($p < 0.05$) except for superior limbus 1S, where 50% of liposomes could still be detected ($p > 0.05$). This is an indication that the residence time for neutral liposomes is much higher at the superior limbus/cornea periphery (**Figure 5** and **Figure 6**) when compared to other regions. The lowest amount of fluorescence was detected in the nasal and inferior regions at all time points due to their distance from the injection site (**Figure 6A,B**).

In more comprehensive studies of clearance of liposomes in the eye previously reported¹, we have discussed a few routes in which liposomes could be cleared from ocular tissues after subconjunctival injection. While liposomes can be cleared by systemic circulation and lymphatic clearance through the conjunctiva, episclera, and choroid, which are highly vascularized, they could also reach deeper intraocular tissues by passive diffusion through the sclera. Fluid flow could also transport the liposomes through the trabecular meshwork or uveosclera outflow, which can bring the liposomes back to the sclera. Elimination through tears is also possible, and minor leakages in the injection site could allow corneal penetration through passive diffusion.

FIGURE AND TABLE LEGENDS:

Figure 1: Subconjunctival injection of liposomes in the eye. (A) Graphical representation of green-fluorescent liposomes and subconjunctival injection. (B) Composition and properties of FL-DHPE doped liposomal formulation for ocular CLM Imaging. (C) Green-fluorescent liposomes forming a bleb upon subconjunctival injection. This figure has been adapted with permission from Chaw S.Y. et al.¹.

Figure 2: Timeline of ocular CLM procedure.

Figure 3: Eye map for CLM scans. Area 1 refers to the limbus region, while area 2 refers to the sclera region. Videos and images were taken from 1T in an anti-clockwise direction, followed by 2T in a similar anti-clockwise direction. As the needle was inserted for injection from 2T towards 2S, areas of interest are mainly 1T, 1S, 2T, and 2S. Insert shows the size of the probe relative to the mouse eye. This figure has been adapted with permission from Chaw S.Y. et al.¹.

Figure 4: Image Analysis. (A) ImageJ analysis of fluorescent-tagged liposomes was done using regions of interest (ROI) defined for the limbus (L) and sclera (S) (B) Ocular regions quantified at the limbus region for liposome presence. Possible locations of liposomes detected in the limbus are 1) corneal periphery, 2) limbus or 3) sclera periphery. This figure has been adapted with permission from Chaw S.Y. et al.¹.

Figure 5: Contrast distributions at the limbus and sclera. Contrast distribution at the limbus (1S: Superior, 1N: Nasal, 1I: Inferior, 1T: Temporal) and sclera (2S: Superior, 2N: Nasal, 2I: Inferior, 2T: Temporal) regions of one representative mouse from each cohort (n=4) over 7 days for (A) Fluorescein (FI) control, (B) 100 nm neutral liposomes (POPC-100). Red color indicates EB staining. Scale bar = 50 μ m. (C) Images taken are assembled on the eye map for better understanding. This figure has been adapted with permission from Chaw S.Y. et al.¹.

Figure 6: Clearance kinetics of 100 nm neutral POPC liposomes at the sclera (A) and limbus (B) regions over 7 days (n=4 mice per group). Mean fluorescence intensity was compared by 2-way ANOVA with multiple comparisons with respect to the previous time point; $d_{1 \rightarrow 3}$ and $d_{3 \rightarrow 7}$; * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.

Figure 7: Representative histology images of transverse sections (5 μ m) of mouse eye one day post-injection of FI-DHPE liposomes. Dotted lines indicate where the liposomes can be observed, indicated by green color. Scale bar = 500 μ m.

DISCUSSION:

As shown from the results, CLM provides a simple and feasible method to image the ocular distribution of liposomes in the eye. We previously demonstrated the use of CLM to characterize the localization of various liposomal formulations within the mouse eye over time¹. For non-invasive applications, CLM permits real-time imaging of the anterior ocular surface for insights on how liposomes are distributed in the eye from the same animal. This makes CLM suitable to pre-screen nanocarrier/DDS prior to more comprehensive quantification. Given the unique

physiochemical properties of diverse DDS, it is rather challenging to characterize its sub-compartment distribution by conventional histology. The latter would require exhaustive sectioning of the whole eye and individual imaging sections by fluorescence microscopy for an overall sense of the DDS clearance.

In agreement with CLM images (**Figure 5B,C**), we could observe green fluorescent signals by histology at the cornea, limbus, and sclera regions of the eye collected at day 1 post-injection of the liposomes (**Figure 7**). Notably, CLM showed better sensitivity than fluorescent microscopy – liposomes at the sclera could be clearly detected using CLM (**Figure 5**) but barely detected by the fluorescence microscope (**Figure 7**). The signal loss could be due to the washing and sectioning procedures that affected the retention of liposomes in tissue sections. Although CLM is limited in pinpointing the exact tissue layer in which the liposomes accumulate, it is definitely a feasible and relatively straightforward method to screen and assess candidate ocular therapeutics non-invasively in real-time.

While other imaging systems like *in vivo* imaging systems and fluorometers also enable live imaging or live quantification of fluorescence in the eye, they are not as suitable for the purpose of this study. *In vivo* imaging systems do not offer the spatial resolution required to define where the therapeutics are in the ocular space. One can only get an idea of whether the therapeutics are still present in the ocular space and their biodistribution when using *in vivo* imaging system²⁰. A fluorometer allows the measurement of fluorescence along the optical axis of the eye and is widely used to study physiological changes in the eye. As there is difficulty getting the exact same optical axis scanned at every time point, a consistent imaging spot cannot be maintained. This is very crucial, especially when studying the distribution of drug delivery systems in which their residence time and clearance rate from the injection site are totally unknown. Furthermore, the injection site and the distribution expected for subconjunctival injection are also not within the range of the optical axis.

Critical steps in the protocol include strictly following an imaging map similar to the eye map shown in **Figure 3** and labeling the locations accurately. Mis-labelling or deviation from imaging location would result in inconsistency of results. As laser intensity can be adjusted for each scan, it is important that the intensity is consistent for the quantification of different time points to be comparable. It is also important that the probe is kept free of debris during the imaging process. As eye mucus can get caught on the probe while imaging, rinsing the probe in saline is recommended if background values rise above the user-defined value.

Other than subconjunctival injection, this CLM system also has the potential to be used to study other ocular delivery routes such as eye drop administration and intravitreal injection (IVT). However, due to the limitation in imaging depth, it might not be as useful for IVT if the injection site and deeper ocular tissues are the main areas of interest. CLM can also be used as a form of intravital imaging to study the distribution of DDS in other organs or tissues. Although it has rarely been employed to study DDS distribution, endoscopic confocal microscopy has been used to image inflammation caused by periodontitis²¹, monitor pulmonary inflammation and

infections^{22,23} and effect of drugs on angiogenesis in tumors²⁴, indicating a range of other possible applications for this CLM system.

Overall, this protocol could serve as a screening step to find out how modifications in DDS formulations affect where they reside or accumulate, which could be critical in the design of a DDS.

ACKNOWLEDGMENTS:

This research was funded by NTU-Northwestern Institute for Nanomedicine (NNIN) grant awarded (to SV) and in part by Singapore National Research Foundation Grant AG/CIV/GC70-C/NRF/2013/2 (to AMC). Thanks to members from Duke-NUS Laboratory for Translational and Molecular Imaging (LTMI) for facilitating the logistics and execution of the studies and training on equipment. Special thanks to Ms. Wisna Novera for her editorial assistance.

DISCLOSURES:


The authors have nothing to disclose.

REFERENCES:

1. Chaw, S. Y., Novera, W., Chacko, A.-M., Wong, T. T. L., Venkatraman, S. In vivo fate of liposomes after subconjunctival ocular delivery. *Journal of Controlled Release*. **329**, 162–174 (2021).
2. Kuo, J. C.-H. et al. Detection of colorectal dysplasia using fluorescently labelled lectins. *Scientific Reports*. **6** (1), 24231 (2016).
3. Wu, Y.-F. et al. A custom multiphoton microscopy platform for live imaging of mouse cornea and conjunctiva. *Journal of Visualized Experiments: JoVE*. **159**, e60944 (2020).
4. Zhivov, A., Stachs, O., Kraak, R., Stave, J., Guthoff, R. F. In vivo confocal microscopy of the ocular surface. *The Ocular Surface*. **4** (2), 81–93 (2006).
5. Bassyouni, F., ElHalwany, N., Abdel Rehim, M., Neyfeh, M. Advances and new technologies applied in controlled drug delivery system. *Research on Chemical Intermediates*. **41** (4), 2165–2200 (2015).
6. Sercombe, L. et al. Advances and challenges of liposome assisted drug delivery. *Frontiers in Pharmacology*. **6**, (2015).
7. Koning, G. A., Storm, G. Targeted drug delivery systems for the intracellular delivery of macromolecular drugs. *Drug Discovery Today*. **8** (11), 482–483 (2003).
8. Metselaar, J. M., Storm, G. Liposomes in the treatment of inflammatory disorders. *Expert Opinion on Drug Delivery*. **2** (3), 465–476 (2005).
9. Ding, B. S., Dziubla, T., Shuvaev, V. V., Muro, S., Muzykantov, V. R. Advanced drug delivery systems that target the vascular endothelium. *Molecular Interventions*. **6** (2), 98–112, (2006).
10. Hua, S., Wu, S. Y. The use of lipid-based nanocarriers for targeted pain therapies. *Frontiers in Pharmacology*. **4**, 143 (2013).
11. Sharma, A., Sharma, U. S. Liposomes in drug delivery: Progress and limitations. *International Journal of Pharmaceutics*. **154** (2), 123–140 (1997).
12. Abrishami, M. M. et al. Preparation, characterization, and *in vivo* evaluation of

- nanoliposomes-encapsulated Bevacizumab (Avastin) for intravitreal administration. *Retina*. **29** (5), 699–703 (2009).
13. Pleyer, U. et al. Ocular absorption of cyclosporine A from liposomes incorporated into collagen shields. *Current Eye Research*. **13** (3), 177–181 (1994).
14. Shen, Y., Tu, J. Preparation and ocular pharmacokinetics of ganciclovir liposomes. *The AAPS Journal*. **9** (3), E371–E377 (2007).
15. Weijtens, O. et al. High concentration of dexamethasone in aqueous and vitreous after subconjunctival injection. *American Journal of Ophthalmology*. **128** (2), 192–197 (1999).
16. Voss, K. et al. Development of a novel injectable drug delivery system for subconjunctival glaucoma treatment. *Journal of Controlled Release*. **214**, 1–11 (2015).
17. Giarmoukakis, A. et al. Biodegradable nanoparticles for controlled subconjunctival delivery of latanoprost acid: In vitro and in vivo evaluation. Preliminary results. *Experimental Eye Research*. **112**, 29–36 (2013).
18. Shah, N. V. et al. Intravitreal and subconjunctival melphalan for retinoblastoma in transgenic mice. *Journal of Ophthalmology*. **2014**, 829879 (2014).
19. Dastjerdi, M. H., Sadrai, Z., Saban, D. R., Zhang, Q. & Dana, R. Corneal Penetration of Topical and Subconjunctival Bevacizumab. *Investigative ophthalmology & visual science*. **52** (12), 8718–8723 (2011).
20. Ezra-Elia, R. et al. Can an in vivo imaging system be used to determine localization and biodistribution of AAV5-mediated gene expression following subretinal and intravitreal delivery in mice? *Experimental Eye Research*. **176**, 227–234 (2018).
21. Movila, A. et al. Intravital endoscopic technology for real-time monitoring of inflammation caused in experimental periodontitis. *Journal of Immunological Methods*. **457**, 26–29 (2018).
22. Vanherp, L. et al. Bronchoscopic fibered confocal fluorescence microscopy for longitudinal in vivo assessment of pulmonary fungal infections in free-breathing mice. *Scientific Reports*. **8** (1), 3009 (2018).
23. Chagnon, F. et al. In vivo intravital endoscopic confocal fluorescence microscopy of normal and acutely injured rat lungs. *Laboratory Investigation*. **90** (6), 824–834 (2010).
24. Yun, J. Y. et al. The effect of near-infrared fluorescence conjugation on the anti-cancer potential of cetuximab. *Laboratory Animal Research*. **34** (1), 30–36 (2018).

A



B

LIPOSOME	COMPOSITION		D_H (nm)	PDI ^b	ZETA POTENTIAL (mV)
	LIPID (%)	FL-DHPE LIPID			
POPC-100	POPC ^a (95)	5%	109 ± 1.5	0.1 ± 0.02	-12 ± 0.6

^aPOPC: 16:0-18:1 PC, ^bPolydispersity index

C





Figure 2










Figure 4

A**Defining Limbus (L) ROI****Defining Sclera (S) ROI****B**








Figure 6

[Click here to access/download;Figure;2021 07 05 Figure 6 Results - Graphs.pdf](#)




Fluorescence Intensity
(a.u.) $\times 10^6$

A



B



- Temporal
- Superior
- ▲ Nasal
- ▼ Inferior

Time (days)




Figure 7





Day 1

Mouse 1

Section 1




Section 2







Section 3

Lens



Mouse 2



Sclera

Retina

Injection Site

Conjunctiva

Limbus

Cornea




Bright Field

Fluorescent



Merged

Merged

Merged



Click here to access/download
Table of Materials
Table of Materials-62685_R1.xls



Ms. Ref. No.: JoVE62685_R1

Title: Spatio-temporal in vivo imaging of ocular drug delivery systems using fiberoptic confocal laser microendoscopy
Journal of Visualized Experiments (JoVE)

We appreciate the editorial comments and have edited accordingly. Textual changes are indicated in red in the main manuscript.

Editorial comments:

1. The use of personal pronouns in the manuscript text has been reduced to fit the journal standard. Some comments to be addressed are included in the manuscript. Please review and revise accordingly.

R: Thank you! Comments are addressed.

2. Please revise the lines to avoid the issue of plagiarism from previously published work: 34-36,315-318,321-324,349-352. Refer to the iThenticate report attached.

R: Revised in Red.

3. Please use uppercase letters to label the figures (replace "a, b, c" with "A, B, C")

R: Edited.

4. Figure 1/4: Please include a title for the figure in the Figure and Table Legends section.

R: Titled included as advised.

5. Figure 2: Please maintain a single space between the numeral and (abbreviated) unit, except in cases of %, x, and ° (i.e., the degree sign; excluding temperature). Examples: 5 mL, 10%, 3°, 100 °C, 3x SSC (e.g., "t = -15 min", etc.). Please do not abbreviate days. Revise "t = 1d" to "t = 1 day".

Please revise "15 mins" to "15 min".

R: Edited.

6. Figure 6: Please revise the X-axis title to "Time (days)"

R: Edited.

7. Please include the reference "Kuo, J. C.-H. et al. Detection of colorectal dysplasia using fluorescently labeled lectins. Scientific Reports. 6 (1), 24231, (2016)" in the manuscript (Reviewer #2, Q11)

R: Included

8. Please include a "NOTE" stating that 20 μL can be accommodated in the subconjunctival space in the manuscript text, preferably below the step mentioning the injected volume in this study is "10 μL " and cite the references included in the rebuttal (Reviewer #3, Q7).

R: Included

ELSEVIER LICENSE TERMS AND CONDITIONS

Mar 16, 2021

This Agreement between Dr. Su Yin Chaw ("You") and Elsevier ("Elsevier") consists of your license details and the terms and conditions provided by Elsevier and Copyright Clearance Center.

License Number	5030810175704
License date	Mar 16, 2021
Licensed Content Publisher	Elsevier
Licensed Content Publication	Journal of Controlled Release
Licensed Content Title	In vivo fate of liposomes after subconjunctival ocular delivery
Licensed Content Author	Su Yin Chaw,Wisna Novera,Ann-Marie Chacko,Tina Tzee Ling Wong,Subbu Venkatraman
Licensed Content Date	Jan 10, 2021
Licensed Content Volume	329
Licensed Content Issue	n/a
Licensed Content Pages	13
Start Page	162
End Page	174

Type of Use	reuse in a journal/magazine
Requestor type	academic/educational institute
Portion	figures/tables/illustrations
Number of figures/tables/illustrations	2
Format	both print and electronic
Are you the author of this Elsevier article?	Yes
Will you be translating?	No
Title of new article	Spatio-temporal in vivo imaging of ocular drug delivery systems using fiberoptic confocal laser microendoscopy
Lead author	Su Yin Chaw
Title of targeted journal	JOVE
Publisher	MyJoVE Corporation
Expected publication date	May 2021
Order reference number	COREL10686
Portions	Figure 1a,b, Figure 2a,b,c
Requestor Location	Dr. Su Yin Chaw 8 college road, #04-45B, Singapore 1698 Singapore, Singapore 169857 Singapore Attn: DUKE-NUS Medical School

Publisher Tax ID

GB 494 6272 12

Total

0.00 USD

Terms and Conditions

INTRODUCTION

1. The publisher for this copyrighted material is Elsevier. By clicking "accept" in connection with completing this licensing transaction, you agree that the following terms and conditions apply to this transaction (along with the Billing and Payment terms and conditions established by Copyright Clearance Center, Inc. ("CCC"), at the time that you opened your Rightslink account and that are available at any time at <http://myaccount.copyright.com>).

GENERAL TERMS

2. Elsevier hereby grants you permission to reproduce the aforementioned material subject to the terms and conditions indicated.

3. Acknowledgement: If any part of the material to be used (for example, figures) has appeared in our publication with credit or acknowledgement to another source, permission must also be sought from that source. If such permission is not obtained then that material may not be included in your publication/copies. Suitable acknowledgement to the source must be made, either as a footnote or in a reference list at the end of your publication, as follows:

"Reprinted from Publication title, Vol /edition number, Author(s), Title of article / title of chapter, Pages No., Copyright (Year), with permission from Elsevier [OR APPLICABLE SOCIETY COPYRIGHT OWNER]." Also Lancet special credit - "Reprinted from The Lancet, Vol. number, Author(s), Title of article, Pages No., Copyright (Year), with permission from Elsevier."

4. Reproduction of this material is confined to the purpose and/or media for which permission is hereby given.

5. Altering/Modifying Material: Not Permitted. However figures and illustrations may be altered/adapted minimally to serve your work. Any other abbreviations, additions, deletions and/or any other alterations shall be made only with prior written authorization of Elsevier Ltd. (Please contact Elsevier's permissions helpdesk [here](#)). No modifications can be made to any Lancet figures/tables and they must be reproduced in full.

6. If the permission fee for the requested use of our material is waived in this instance, please be advised that your future requests for Elsevier materials may attract a fee.

7. Reservation of Rights: Publisher reserves all rights not specifically granted in the combination of (i) the license details provided by you and accepted in the course of this licensing transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment terms and conditions.

8. License Contingent Upon Payment: While you may exercise the rights licensed immediately upon issuance of the license at the end of the licensing process for the transaction, provided that you have disclosed complete and accurate details of your proposed

use, no license is finally effective unless and until full payment is received from you (either by publisher or by CCC) as provided in CCC's Billing and Payment terms and conditions. If full payment is not received on a timely basis, then any license preliminarily granted shall be deemed automatically revoked and shall be void as if never granted. Further, in the event that you breach any of these terms and conditions or any of CCC's Billing and Payment terms and conditions, the license is automatically revoked and shall be void as if never granted. Use of materials as described in a revoked license, as well as any use of the materials beyond the scope of an unrevoked license, may constitute copyright infringement and publisher reserves the right to take any and all action to protect its copyright in the materials.

9. Warranties: Publisher makes no representations or warranties with respect to the licensed material.

10. Indemnity: You hereby indemnify and agree to hold harmless publisher and CCC, and their respective officers, directors, employees and agents, from and against any and all claims arising out of your use of the licensed material other than as specifically authorized pursuant to this license.

11. No Transfer of License: This license is personal to you and may not be sublicensed, assigned, or transferred by you to any other person without publisher's written permission.

12. No Amendment Except in Writing: This license may not be amended except in a writing signed by both parties (or, in the case of publisher, by CCC on publisher's behalf).

13. Objection to Contrary Terms: Publisher hereby objects to any terms contained in any purchase order, acknowledgment, check endorsement or other writing prepared by you, which terms are inconsistent with these terms and conditions or CCC's Billing and Payment terms and conditions. These terms and conditions, together with CCC's Billing and Payment terms and conditions (which are incorporated herein), comprise the entire agreement between you and publisher (and CCC) concerning this licensing transaction. In the event of any conflict between your obligations established by these terms and conditions and those established by CCC's Billing and Payment terms and conditions, these terms and conditions shall control.

14. Revocation: Elsevier or Copyright Clearance Center may deny the permissions described in this License at their sole discretion, for any reason or no reason, with a full refund payable to you. Notice of such denial will be made using the contact information provided by you. Failure to receive such notice will not alter or invalidate the denial. In no event will Elsevier or Copyright Clearance Center be responsible or liable for any costs, expenses or damage incurred by you as a result of a denial of your permission request, other than a refund of the amount(s) paid by you to Elsevier and/or Copyright Clearance Center for denied permissions.

LIMITED LICENSE

The following terms and conditions apply only to specific license types:

15. **Translation:** This permission is granted for non-exclusive world **English** rights only unless your license was granted for translation rights. If you licensed translation rights you may only translate this content into the languages you requested. A professional translator must perform all translations and reproduce the content word for word preserving the integrity of the article.

16. Posting licensed content on any Website: The following terms and conditions apply as follows: Licensing material from an Elsevier journal: All content posted to the web site must maintain the copyright information line on the bottom of each image; A hyper-text must be included to the Homepage of the journal from which you are licensing at <http://www.sciencedirect.com/science/journal/xxxxx> or the Elsevier homepage for books at <http://www.elsevier.com>; Central Storage: This license does not include permission for a scanned version of the material to be stored in a central repository such as that provided by Heron/XanEdu.

Licensing material from an Elsevier book: A hyper-text link must be included to the Elsevier homepage at <http://www.elsevier.com>. All content posted to the web site must maintain the copyright information line on the bottom of each image.

Posting licensed content on Electronic reserve: In addition to the above the following clauses are applicable: The web site must be password-protected and made available only to bona fide students registered on a relevant course. This permission is granted for 1 year only. You may obtain a new license for future website posting.

17. For journal authors: the following clauses are applicable in addition to the above:

Preprints:

A preprint is an author's own write-up of research results and analysis, it has not been peer-reviewed, nor has it had any other value added to it by a publisher (such as formatting, copyright, technical enhancement etc.).

Authors can share their preprints anywhere at any time. Preprints should not be added to or enhanced in any way in order to appear more like, or to substitute for, the final versions of articles however authors can update their preprints on arXiv or RePEc with their Accepted Author Manuscript (see below).

If accepted for publication, we encourage authors to link from the preprint to their formal publication via its DOI. Millions of researchers have access to the formal publications on ScienceDirect, and so links will help users to find, access, cite and use the best available version. Please note that Cell Press, The Lancet and some society-owned have different preprint policies. Information on these policies is available on the journal homepage.

Accepted Author Manuscripts: An accepted author manuscript is the manuscript of an article that has been accepted for publication and which typically includes author-incorporated changes suggested during submission, peer review and editor-author communications.

Authors can share their accepted author manuscript:

- immediately
 - via their non-commercial person homepage or blog
 - by updating a preprint in arXiv or RePEc with the accepted manuscript
 - via their research institute or institutional repository for internal institutional uses or as part of an invitation-only research collaboration work-group
 - directly by providing copies to their students or to research collaborators for their personal use
 - for private scholarly sharing as part of an invitation-only work group on commercial sites with which Elsevier has an agreement
- After the embargo period

- via non-commercial hosting platforms such as their institutional repository
- via commercial sites with which Elsevier has an agreement

In all cases accepted manuscripts should:

- link to the formal publication via its DOI
- bear a CC-BY-NC-ND license - this is easy to do
- if aggregated with other manuscripts, for example in a repository or other site, be shared in alignment with our hosting policy not be added to or enhanced in any way to appear more like, or to substitute for, the published journal article.

Published journal article (JPA): A published journal article (PJA) is the definitive final record of published research that appears or will appear in the journal and embodies all value-adding publishing activities including peer review co-ordination, copy-editing, formatting, (if relevant) pagination and online enrichment.

Policies for sharing publishing journal articles differ for subscription and gold open access articles:

Subscription Articles: If you are an author, please share a link to your article rather than the full-text. Millions of researchers have access to the formal publications on ScienceDirect, and so links will help your users to find, access, cite, and use the best available version.

Theses and dissertations which contain embedded PJAs as part of the formal submission can be posted publicly by the awarding institution with DOI links back to the formal publications on ScienceDirect.

If you are affiliated with a library that subscribes to ScienceDirect you have additional private sharing rights for others' research accessed under that agreement. This includes use for classroom teaching and internal training at the institution (including use in course packs and courseware programs), and inclusion of the article for grant funding purposes.

Gold Open Access Articles: May be shared according to the author-selected end-user license and should contain a [CrossMark logo](#), the end user license, and a DOI link to the formal publication on ScienceDirect.

Please refer to Elsevier's [posting policy](#) for further information.

18. For book authors the following clauses are applicable in addition to the above: Authors are permitted to place a brief summary of their work online only. You are not allowed to download and post the published electronic version of your chapter, nor may you scan the printed edition to create an electronic version. **Posting to a repository:** Authors are permitted to post a summary of their chapter only in their institution's repository.

19. Thesis/Dissertation: If your license is for use in a thesis/dissertation your thesis may be submitted to your institution in either print or electronic form. Should your thesis be published commercially, please reapply for permission. These requirements include permission for the Library and Archives of Canada to supply single copies, on demand, of the complete thesis and include permission for Proquest/UMI to supply single copies, on demand, of the complete thesis. Should your thesis be published commercially, please reapply for permission. Theses and dissertations which contain embedded PJAs as part of the formal submission can be posted publicly by the awarding institution with DOI links back to the formal publications on ScienceDirect.

Elsevier Open Access Terms and Conditions

You can publish open access with Elsevier in hundreds of open access journals or in nearly 2000 established subscription journals that support open access publishing. Permitted third party re-use of these open access articles is defined by the author's choice of Creative Commons user license. See our [open access license policy](#) for more information.

Terms & Conditions applicable to all Open Access articles published with Elsevier:

Any reuse of the article must not represent the author as endorsing the adaptation of the article nor should the article be modified in such a way as to damage the author's honour or reputation. If any changes have been made, such changes must be clearly indicated.

The author(s) must be appropriately credited and we ask that you include the end user license and a DOI link to the formal publication on ScienceDirect.

If any part of the material to be used (for example, figures) has appeared in our publication with credit or acknowledgement to another source it is the responsibility of the user to ensure their reuse complies with the terms and conditions determined by the rights holder.

Additional Terms & Conditions applicable to each Creative Commons user license:

CC BY: The CC-BY license allows users to copy, to create extracts, abstracts and new works from the Article, to alter and revise the Article and to make commercial use of the Article (including reuse and/or resale of the Article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made and the licensor is not represented as endorsing the use made of the work. The full details of the license are available at <http://creativecommons.org/licenses/by/4.0>.

CC BY NC SA: The CC BY-NC-SA license allows users to copy, to create extracts, abstracts and new works from the Article, to alter and revise the Article, provided this is not done for commercial purposes, and that the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made and the licensor is not represented as endorsing the use made of the work. Further, any new works must be made available on the same conditions. The full details of the license are available at <http://creativecommons.org/licenses/by-nc-sa/4.0>.

CC BY NC ND: The CC BY-NC-ND license allows users to copy and distribute the Article, provided this is not done for commercial purposes and further does not permit distribution of the Article if it is changed or edited in any way, and provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, and that the licensor is not represented as endorsing the use made of the work. The full details of the license are available at <http://creativecommons.org/licenses/by-nc-nd/4.0>. Any commercial reuse of Open Access articles published with a CC BY NC SA or CC BY NC ND license requires permission from Elsevier and will be subject to a fee.

Commercial reuse includes:

- Associating advertising with the full text of the Article
- Charging fees for document delivery or access
- Article aggregation
- Systematic distribution via e-mail lists or share buttons

Posting or linking by commercial companies for use by customers of those companies.

20. Other Conditions:

v1.10

Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or +1-978-646-2777.
